These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15755296)

  • 1. Pulmonary hypertension and thalidomide therapy in multiple myeloma.
    Hattori Y; Shimoda M; Okamoto S; Satoh T; Kakimoto T; Ikeda Y
    Br J Haematol; 2005 Mar; 128(6):885-7; author reply 887-8. PubMed ID: 15755296
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.
    Antonioli E; Nozzoli C; Gianfaldoni G; Mannelli F; Rossi S; Betti S; Bernardeschi P; Fiorentini G; Bosi A
    Ann Oncol; 2005 Nov; 16(11):1849-50. PubMed ID: 16012178
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma.
    Cany L; Fitoussi O; Boiron JM; Marit G
    J Clin Oncol; 2002 Apr; 20(8):2212. PubMed ID: 11956286
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.
    Younis TH; Alam A; Paplham P; Spangenthal E; McCarthy P
    Br J Haematol; 2003 Apr; 121(1):191-2. PubMed ID: 12670354
    [No Abstract]   [Full Text] [Related]  

  • 6. Thalidomide-associated gynecomasty in a patient with multiple myeloma.
    Pulik M; Genet P; Lionnet F; Touahri T
    Am J Hematol; 2002 Jul; 70(3):265. PubMed ID: 12111777
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 8. Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
    Boga C; Ozdogu H; Yeral M; Kizilkilic E; Tamer L
    J Support Oncol; 2007 Jun; 5(6):256. PubMed ID: 17624049
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.
    Prasad HK; Kaushal V; Mehta P
    Am J Hematol; 2007 Sep; 82(9):855-7. PubMed ID: 17570510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide therapy and polyneuropathy in myeloma patients.
    Laaksonen S; Remes K; Koskela K; Voipio-Pulkki LM; Falck B
    Electromyogr Clin Neurophysiol; 2005 Mar; 45(2):75-86. PubMed ID: 15861857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide.
    Petropoulou AD; Gerotziafas GT; Samama MM; Hatmi M; Rendu F; Elalamy I
    Thromb Res; 2008; 121(4):493-7. PubMed ID: 17618677
    [No Abstract]   [Full Text] [Related]  

  • 15. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible dementia due to thalidomide therapy for multiple myeloma.
    Morgan AE; Smith WK; Levenson JL
    N Engl J Med; 2003 May; 348(18):1821-2. PubMed ID: 12724497
    [No Abstract]   [Full Text] [Related]  

  • 17. Thalidomide for the treatment of leptomeningeal multiple myeloma.
    Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
    Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study.
    Lafaras C; Mandala E; Verrou E; Platogiannis D; Barbetakis N; Bischiniotis T; Zervas K
    Ann Oncol; 2008 Oct; 19(10):1765-9. PubMed ID: 18480066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
    Huston A; Brown J; Roodman GD
    Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
    [No Abstract]   [Full Text] [Related]  

  • 20. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.